Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2018, Vol. 40 ›› Issue (3): 411-414.doi: 10.3881/j.issn.1000-503X.2018.03.020

• Review Articles • Previous Articles     Next Articles

Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer

ZHANG Jiaying1,ZHU Lei1,YANG Hongkuan1,CHEN Fang2()   

  1. 1 First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China
    2 Department of Lung Function,First Affiliated Hospital,Zhejiang Chinese Medicine University,Hangzhou 310006,China
  • Received:2017-10-30 Online:2018-06-30 Published:2018-07-05
  • Supported by:
    Supported by the Traditional Chinese Medicine Science Research Foundation of Zhejiang(2018ZA039)


The past few years have witnessed rapid advances in the immunotherapies for non-small-cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic vaccine against lung cancer independently developed by Cuba. It can exert its anti-tumor effect by forming epidermal growth factor (EGF) antibodies to block the binding of EGF to EGF receptor. So far stage both phases Ⅱ and Ⅲ trials have proved its effectiveness and long-term safety,and phases Ⅲ and Ⅳ trials are underway. A deeper understanding of the role of CIMAvax-EGF in NSCLC will accelerate the application of immunotherapy. This article summarizes the recent advances of CIMAvax-EGF R&D and its application in treating NSCLC.

Key words: CIMAvax-EGF, vaccine, non-small-cell lung cancer, epidermal growth factor, immunotherapy

CLC Number: